Aspirin

SEP 4, 2026 · PHASE 3 TRIAL

Aspirin in Preventing Recurrence of Cancer in Patients With HER2 Negative Stage II-III Breast Cancer After Chemotherapy, Surgery, and/or Radiation Therapy

ClinicalTrials.gov

This is a terminated Phase 3 RCT registry record with no posted results; the study design is rigorous but no outcome data are available to assess efficacy or harm.

JUN 18, 2026 · REGULATORY LABEL UPDATE

FDA supplemental approval: Hydrocodone Bitartrate AND Aspirin (REMS)

U.S. Food and Drug Administration

FDA supplemental approval action establishing a REMS (Risk Evaluation and Mitigation Strategy) for an existing hydrocodone bitartrate and aspirin combination product; this record documents regulatory authorization but does not report clinical trial outcomes or efficacy data.

JUN 18, 2026 · REGULATORY LABEL UPDATE

FDA supplemental approval: Oxycodone AND Aspirin (REMS)

U.S. Food and Drug Administration

FDA supplemental approval action for oxycodone and aspirin combination tablet with REMS requirement; does not report clinical trial outcomes or comparative efficacy.